Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Item

http://www.wikidata.org/entity/Q37121685

Q37121685

about

Tumor angiogenesis: pericytes and maturation are not to be ignored Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Biomarkers of cancer angioprevention for clinical studies Optimal combination of antiangiogenic therapy for hepatocellular carcinoma Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review Targeting angiogenesis in gynecologic cancers Targeting triple-negative breast cancer: optimising therapeutic outcomes The role of vascular endothelial growth factor a polymorphisms in breast cancer Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment Anti-vascular endothelial growth factor therapy in breast cancer Pharmacogenomics of breast cancer therapy: an update The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors Systemic therapies for pancreatic cancer--the role of pharmacogenetics Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303 Normalization of the vasculature for treatment of cancer and other diseases.Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients Bevacizumab and breast cancer: current therapeutic progress and future perspectives Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life.Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.

P2860

Q21296683-130C2EBF-ACEF-46E3-88C2-B40D73D28ABA Q24595773-329C9DD4-0FCC-4151-9D10-9451D49ECF7B Q26752752-4C9D0D61-F9F8-4DE0-BEEB-99F20C200D45 Q26774580-70E9CF64-64DC-49BC-BE62-A4152B25FD9B Q26799458-88CA8BFF-7E0A-4980-B488-DFCF76B04CEF Q26822432-88DC4328-3D33-4724-A83B-A05A8B05C819 Q26824086-A9234563-2E0B-4298-AE65-63B250B2F814 Q26824766-2D0B573E-4E15-4199-BE44-F13C9E4FD967 Q26850892-808F1690-4BE5-4D5A-83DF-C4D7AD66562D Q26851522-6C3F1FDD-9A52-4572-AEFF-1F1C75ECFA08 Q26859144-AEAF1196-F3AE-4573-8793-8DF8BC198678 Q26996793-E96483BC-AB12-46E5-A0E6-D65128DEC7BF Q26999473-FCF0BA82-98C0-4949-8DF3-DA07599E093E Q27006783-5F390CA7-CA87-474F-BBD4-A86EBF3F96DD Q27011540-31E8DBD7-8C94-4B5A-8261-BB91C7ABA512 Q27021716-83AB7448-5480-4CF8-96FD-5549416B2DC5 Q27302122-D90557CB-CFDD-4D41-B777-FFACC1562093 Q27851744-99594C81-875D-4162-B2DD-6A43AF8FA940 Q27853168-042FCCED-264A-4DA5-9621-8B6A331AD8F3 Q28080469-8818C264-A83E-4BC4-ABFA-0B9BF8449C6E Q28388270-4A6ACB38-F259-48F7-85D8-4D852F0BF36B Q28943270-C40052EF-FB57-4ED5-A824-B9BF2E616984 Q30471456-A75A5E3A-3C57-446F-B4C2-A6C6008CE2BC Q30537414-EEF747A3-5C74-487B-A2E4-1D945967F41B Q30587082-925E5865-F692-4822-BB93-790998AFF5A7 Q33384665-7D587825-ABE2-489C-B493-1E754278666F Q33397464-FA951C17-65BB-4412-8520-E594DDE43317 Q33404543-A6F29CD7-EEC8-409D-9980-36553CAD0150 Q33413566-8BAB1475-22AE-4D0C-9190-EF5880041654 Q33417324-05A857F4-1E20-4214-AFD8-7CA8B3225D72 Q33418562-C70D11B5-4A16-441B-AD3D-D99A4D3AA055 Q33426958-D931A7C1-DA14-4545-937F-9AF7792FA5C7 Q33640753-BE3206CF-C947-4308-9473-A94D1AE5F1AA Q33684042-9C0D8DBD-3C2D-49B9-80EC-71B1E1164315 Q33703527-725F7698-5539-4651-A034-EFBAFD3804DB Q33710753-EB54FC54-88A9-498F-8C10-B4155C109FC8 Q33803564-AC8CC965-E7F8-43EC-9C94-B0D7CFF79938 Q33807542-C0D1EB6D-582B-4679-B40E-BB179D77F9A4 Q33813718-255635BC-53FB-485A-B67E-F6968DE1D3EB Q33834417-CF121D84-BAA8-499B-BA80-4CDAE56988E1

P2860

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Item

http://www.wikidata.org/entity/Q37121685

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs